Echo Therapeutics (NSDQ:ECTE) said it inked a deal to license its Symphony continuous glucose monitor for the Chinese market, sending share prices up this week.
Funding Roundup
IPOs reach pre-bubble highs in 2013
The market for initial public offerings in the U.S. hit a high this year not seen since the tech bubble burst in the early 2000s, with more than 222 IPOs expected before the end of 2013.
The 6 offerings priced Dec. 11 brought the annual IPO total to 218, beating the post-bubble peak of 217 reached in 2004 and eclipsing the most recent high of 213 in 2007, according to Renaissance Capital.
CareFusion puts $100M in Israeli infusion pumps
CareFusion (NYSE:CFN) announced today that it invested $100 million into Israel-based Caesarea Medical Electronics, taking a 40% stake in the infusion pump company.
Soft Tissue Regeneration raises $4.7M for biodegradable scaffold
Orthopedics maker Soft Tissue Regeneration is closing in on a $5 million funding round, with $4.7 million raised so far.
The New Haven, Conn.-based company is raising funds through sales of equity, options, warrants and other securities, with 14 unnamed investors listed so far in regulatory filings.
Echo Therapeutics announces $15M offering
Echo Therapeutics (NSDQ:ECTE) is offering 3.2 million shares of its common stock in hopes of raising about $15 million.
Lumenis files for $115M IPO
Lumenis Ltd., an Israeli medtech company that makes lasers used in eye surgery, urology and cosmetic medical procedures, filed today for an initial public offering worth $115 million.
Yokneam, Israel-based Lumenis said it plans to trade on the NASDAQ stock exchange under the "LMNS" symbol.
Endologix offers $75M in convertible notes
C.R. Bard lands $46M Dept. of Defense contract extension
Trice Orthopedics lands $3M bridge loan
Trice Orthopedics said it closed a bridge loan financing worth about $3 million.
The King Of Prussia, Pa.-based medical device company said BioStar Ventures led the round, along with Millennium Life Sciences, existing investors and several new private backers.
Xlumena wraps up $25M Series C round
Xlumena said it closed a $25 million Series C round it plans to use to expand its commercial footprint and win FDA clearance for its Axios stent and delivery system.
Inogen registers for $86M IPO
Inogen registered for an initial public offering worth up to $86.3 million IPO, saying it plans to will trade on the NASDAQ exchange under the INGN symbol.
The Goleta, Calif.-based medical device company makes oxygen concentrators used to deliver supplemental oxygen therapy to patients suffering from chronic respiratory conditions.